James Park Senior Analyst, Deal Intelligence.
Former McKinsey consultant covering pharma M&A. Tracks global licensing transactions, deal structures, and market valuations.
Biotech & Pharma Conferences 2027: The Dealmaker’s Calendar
The partnering meetings, scientific congresses and regional forums that shape the 2027 biotech deal year, with confirmed dates and cities for JPM, BIO-Europe, ChinaBio, AACR, ASCO, BIO and more, the 2027 clashes, and which meetings fit which goal.
HKEX Chapter 18A: How Pre-Revenue China Biotechs IPO in Hong Kong (2026)
How pre-revenue China biotechs list in Hong Kong under HKEX Chapter 18A: the eligibility bar (HK$1.5B market cap, a Core Product through Phase 1, a sophisticated investor, the "-B" marker), the post-2024 recovery (14 new 18A listings in 2025), 18A vs Chapter 18C vs the STAR Market, lock-ups, and how a pending listing reshapes leverage in an out-licensing or M&A negotiation.
China's Biotech Innovation Clusters: A Site-Selection & Partner-Sourcing Map (2026)
Where to base a NewCo and scout assets across China's four biotech clusters — Suzhou BioBAY, Shanghai Zhangjiang, Beijing Zhongguancun and the Greater Bay Area — with incentives, anchor companies, guiding funds and entry routes for Western firms.
Who Funds China Biotech: The Cross-Border Investor & VC Map (2026)
A dealmaker’s map of who actually funds China biotech in 2026 — the USD vs RMB two-pool fund structure post-BIOSECURE, license-out as a financing substitute, VCs moving upstream into labs, and how a Western strategic or fund co-invests or builds a NewCo alongside Qiming, OrbiMed, LAV, Hillhouse and 5Y.
Best Biotech Deal Advisors & Investment Banks 2026: An Objective Comparison
The leading biotech and pharma deal advisors and investment banks in 2026, compared by deal focus, geography, and engagement model — from bulge-bracket banks to specialist life-science banks to cross-border BD & licensing leaders.
AI in Drug Development 2026: The Dealmaker’s Guide
A business-development view of AI drug discovery: market size, the $11B funding wave, the platform landscape, the first clinical proof points (Insilico’s rentosertib), and how pharma actually buys AI through partnerships.
AI Drug Discovery Companies: The 2026 Power List
The leading AI drug discovery companies in 2026 ranked by capital and clinical validation — Isomorphic Labs, Xaira, Recursion, Insilico, Generate, Iambic, XtalPi and more — with a dealmaker’s read on who is real.
AI Drug Discovery Deal Tracker 2026: Partnerships & M&A
A running tracker of the major AI drug discovery deals — Isomorphic–Lilly/Novartis/J&J, Lilly–NVIDIA, Recursion–Roche, Noetik–GSK — with upfronts, biobucks, and a dealmaker’s analysis of the structures.
Most-Favored-Nation Drug Pricing, Explained
What most-favored-nation (MFN) drug pricing means, the 2025 executive order and its mechanics, how it interacts with IRA negotiation and international reference pricing, and what it means for pharma strategy, launch sequencing, and cross-border licensing economics.
Radiopharmaceutical Licensing & Deal Landscape 2026
The radiopharmaceutical market is the hottest modality in oncology dealmaking — over $13B in M&A since 2023. A dealmaker’s guide to the deals (BMS–RayzeBio, AstraZeneca–Fusion, Lilly–POINT), the players, the isotope supply crunch, and the China cross-border angle.
siRNA & Oligonucleotide Licensing Landscape 2026
The siRNA and oligonucleotide modality: approved products (Alnylam, Ionis, inclisiran), the move beyond the liver, the deal and M&A wave, key players, and the China cross-border sourcing opportunity for RNA-silencing assets.
Biotech Investment Banking: The Complete Guide for 2026
Complete guide to biotech investment banking: top life science IB firms, deal types (M&A, IPO, licensing), valuation methods, and how to choose the right advisor for your transaction.
Life Sciences M&A in 2026: Deals, Drivers and Synergy Targets
What is happening in life sciences M&A, what is driving it, the largest biopharma, tools, diagnostics and CDMO deals of 2026, and the synergies buyers are promising.
Biotech Venture Capital 2026: Definitive Investor Guide
$30.5B of biopharma venture funding in 2025 (J.P. Morgan). Top VC firms, investment stages, therapeutic area preferences, geographic trends, and the NewCo/platform creation trend reshaping biotech funding.
Biotech Licensing Deal Tracker 2026: Top Deals, Trends & Strategic Analysis
A record $274B in 2025 and $221B through Q3 2026. Our verified 2026 licensing deal log with upfronts, totals and sources, plus China’s growing share.
Biosimilars & Patent Cliff Licensing 2026: $100B+ Revenue at Risk
Humira, Stelara, Keytruda — the biggest patent cliffs in pharma history are creating a $39.6B biosimilar market. Licensing guide for BD executives.
Pharma M&A Tracker 2026: Every Major Acquisition & What's Driving the Surge
$138.9B in biopharma M&A through Q3 2026, already above all of 2025. Our verified log of 2026’s $1B+ acquisitions, with prices, premiums and CVRs.
Pharma Deals Database 2026: Major Licensing and M&A Deals, Verified
A searchable, downloadable database of 2026’s major pharma licensing deals and acquisitions, each verified against its source, with terms, areas and monthly totals.
rNPV Valuation Guide: The Gold Standard for Pharma Asset Valuation
A practical, step-by-step guide to risk-adjusted NPV—the methodology behind every major pharma licensing deal and acquisition.
Biotech IPO & Funding Landscape 2026: The Window Reopens
The biotech IPO window reopened in 2026 after a 2025 low: 22 IPOs raised $7.5B through Q3. Track the biggest offerings, venture trends, and what makes a successful biotech IPO.
Pharma Due Diligence Checklist: The Complete Guide for Licensing & M&A
A comprehensive, practical checklist covering scientific, IP, regulatory, commercial, financial, and manufacturing due diligence for pharma deals.
Biotech M&A 2026: Navigating the $200B Patent Cliff
A technical analysis of valuation multiples and integration savings in the consolidation wave.